Oversubscribed Financing Paves Path to NDA Submission and Pre-commercialization Efforts for upacicalcet RESEARCH TRIANGLE PARK, N.C. , Aug.
20, 2024 /PRNewswire/ -- Pathalys Pharma, Inc., a private biopharmaceutical company in the late stages of developing treatments for kidney disease, has successfully closed a $105 million Series B financing round. The oversubscribed financing was led by TCGX and joined by other notable investors including, JP Morgan Life Sciences Private Capital, Samsara BioCapital, Marshall Wace , KB Investment, JPS Growth Investment Limited Partnership, and included support from Pathalys' founding investors, Catalys Pacific and DaVita Venture Group.
"Since our inception, Pathalys has made significant strides toward our goal of delivering a best-in-class treatment for those with end-stage kidney disease (ESKD), including the near completion of two phase 3 clinical trials for upacicalcet," said Neal Fowler , Chief Executive Officer at Pathalys Pharma, Inc. "We believe the continued expansion of our syndicate of prominent life science investors, with representative board members, is indicative of the fact that we are on the right path at Pathalys. We are immensely grateful for the continued support of our investors and remain steadfast and confident in our mission to bring upacicalcet forward to patients.
" "I am thrilled to support the Pathalys Pharma team in bringing upacicalcet to dialysis patients with ESKD who need improved calcimimetic treatment option.